RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia
SUMMARY Objective : High-density lipoprotein (HDL)-associated paraoxonase ( PON ) activity may play an important role in the inhibition of low-density lipoprotein ( LDL ) oxidation . Previous studies have demonstrated that serum PON activity is decreased in patients with hyperlipoproteinaemia and coronary heart disease . The study presented here examined the effect of short-term treatment with simvastatin and atorvastatin on lipids and PON activity in patients with hyperlipoproteinaemia . Research design and methods : A prospect i ve , non-blinded , single-group , cross-over , comparative trial was performed . Following an 8-week dietary run-in period , 49 patients ( 23 men and 26 women , mean age : 59.8 ± 7.9 years ) with Fredrickson type IIa . and IIb . hyperlipoproteinaemias were r and omized to receive either simvastatin 20 mg/day or atorvastatin 10 mg/day for 3 months . Following an 8-week washout period , patients were crossed-over to receive the other drug for a further 3 months . Serum lipids were measured and serum PON activity was determined spectrophotometrically using paraoxon as a substrate . Results : Simvastatin treatment significantly reduced serum cholesterol , LDL-cholesterol ( LDL-C ) and apolipoprotein ( apo ) B levels ( p < 0.001 ) . Atorvastatin had a more pronounced cholesterol , LDL-C- and apo B-lowering effect ( p < 0.001 ) compared with simvastatin . Both statins also significantly reduced serum triglyceride levels  ( p < 0.01 ) . Simvastatin and atorvastatin caused no significant change in the levels of HDL-cholesterol ( HDL-C ) and apo A1 . HDL-associated PON activity did not change significantly after simvastatin therapy , but significantly increased after atorvastatin treatment ( p < 0.05 ) . Conclusions : Short-term administration of simvastatin did not increase PON activity  . Atorvastatin treatment had a favourable effect on lipid profile and increased the activity of HDL-associated PON
RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .